Hedge fund Davidson Kempner is recommending that Qiagen NV renegotiate its planned takeover deal with Thermo Fisher Scientific, arguing the demand for diagnostics fueled by the COVID-19 pandemic makes Qiagen worth more than the price agreed to in March.
Thermo Fisher Scientific agreed to buy Qiagen for $11.5bn on 3 March. The offer of €39 per share in cash...